$ZYME News

JP Morgan Maintains Overweight on Zymeworks, Raises Price Target to $33

Zymeworks (ZYME), What Is Behind The Renewed Attention?

Is Zymeworks (ZYME) Stock Fully Priced After Its 301% Run?

Zymeworks: Transitioning Into A Royalty-Driven Biopharma Platform Post Ziihera Approval

SJM, ZYME Stocks Hit 52-Week High – What’s Driving The Surge Today?

Citigroup Maintains Buy on Zymeworks, Raises Price Target to $38

Citizens Reiterates Market Outperform on Zymeworks, Maintains $32 Price Target

HC Wainwright & Co. Maintains Buy on Zymeworks, Raises Price Target to $55

U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma

Zymeworks Announces Participation in Upcoming Investor Conferences

B. Riley Securities Reiterates Buy on Zymeworks, Raises Price Target to $44

Wells Fargo Maintains Overweight on Zymeworks, Raises Price Target to $40

Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $32

Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates

HC Wainwright & Co. Maintains Buy on Zymeworks, Raises Price Target to $51

A Post Acquisition Look At Zymeworks

Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026

Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $31

Zymeworks (ZYME) Stock Looks Fully Valued Despite Its 205% Three Year Run

Here's Why Zymeworks Inc. Paid $929M For Theravance Biopharma